GHGHHealthcare · Diagnostics & Research

GH Stock Forecast: Guardant Health, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$146
+0.24% on the day

The 26 Wall Street analysts covering Guardant Health, Inc. hold a median 12-month price target of $200 — +37.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 46 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$19.7B
Ticker Nerd rank
46/ 100
Median analyst target
$200
Analysts covering
26
Revenue$335.0M+44.3% y/y
Operating income−$129.1M
Net income−$120.1M
Free cash flow−$69.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−10.2%
YTD
+42.9%
1Y
+45.5%
From 52W high
−22.0%
From 52W low
+85.7%
$79
$187
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Guardant Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
46/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Volatility
60
Accruals
60
Growth
60
Quality
58
Revisions
54
Value
43
Issuance
13

Momentum (98): The shares have been drifting up relative to others.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Jan 26Apr 26Jul 26Oct 26GHHigh $240Median $200Low $105

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says26 analysts
25
Buy
0
Hold
1
Sell
$105
Low
$200
Median
$240
High

The green dot is the last close — the median target sits +37.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 16 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Nov 2026Piper SandlerMaintainsOverweight$193 → $190
27 Oct 2026BTIGMaintainsBuy$195 → $210
23 Oct 2026Roth CapitalInitiatesBuy$200
13 Oct 2026Morgan StanleyMaintainsOverweight$185 → $200
7 Oct 2026BarclaysMaintainsOverweight$200 → $220
1 Oct 2026GuggenheimMaintainsBuy$190 → $200
9 Sept 2026UBSMaintainsBuy$175 → $225
8 Sept 2026Rothschild & CoInitiatesBuy$203
2 Sept 2026BTIGReiteratesBuy$195
4 Aug 2026Morgan StanleyMaintainsOverweight$175 → $185
4 Aug 2026Piper SandlerMaintainsOverweight$135 → $193
4 Aug 2026Stephens & Co.MaintainsOverweight$170 → $195
3 Aug 2026StifelMaintainsBuy$130 → $180
31 July 2026BarclaysMaintainsOverweight$150 → $200
31 July 2026BTIGMaintainsBuy$190 → $195
31 July 2026JP MorganMaintainsOverweight$185 → $195
31 July 2026MizuhoMaintainsOutperform$175 → $200
31 July 2026RBC CapitalMaintainsOutperform$185 → $200
31 July 2026TD CowenMaintainsBuy$200 → $210
16 July 2026GuggenheimMaintainsBuy$160 → $190

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GH.

Market Radar

This page is one stock. Monday covers all of them.

GH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Guardant Health, Inc. returned +45.5% against +6.9% for the S&P 500, dividends included.

GH vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26GHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
15.3×

Cheaper than 9% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
65.4%

Higher than 79% of US stocks

Operating margin
−39.4%

Higher than 19% of US stocks

Net margin
−37.9%

Higher than 12% of US stocks

Returns & dividend
Return on equity
—
Return on assets
−19.9%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Guardant Health, Inc. has a market value of $19.7B and an enterprise value of $20.4B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 44.3% year on year.

  • Net income over the same four quarters: −$453.4M, a −38.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.49.

  • Free cash flow in the twelve months to 30 June 2026: −$240.7M.

  • Guardant Health, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 133.6M.

  • Guardant Health, Inc. employs 2,490 people — $475K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

GH and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
GHGuardant Health, Inc.$19.7B46
MEDPMedpace Holdings, Inc.$17.4B93
RVTYRevvity, Inc.$16.2B97
CRLCharles River Laboratories International, Inc.$15.5B87
ICLRICON plc$14.3B75
DGXQuest Diagnostics, Inc.$28.7B93
ILMNIllumina, Inc.$29.1B95

Take a look at GH’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Guardant Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GH

What is the GH stock price forecast for 2026-2027?

The 26 Wall Street analysts covering Guardant Health, Inc. have a median 12-month price target of $200, with estimates ranging from $105 to $240. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GH stock a buy right now?

Of the 26 analysts covering Guardant Health, Inc., 25 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Guardant Health, Inc. 46 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GH?

As at 21 Nov 2026, Guardant Health, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will GH stock go up?

No one can know that. What the data says: the median 12-month target from 26 analysts implies +37.0% from the last close, and Ticker Nerd's factor model ranks Guardant Health, Inc. 46 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GH stock forecast for 2030?

No analyst covering Guardant Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $240 over the next 12 months.

How has GH stock performed over the past year?

Guardant Health, Inc. returned +45.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Guardant Health, Inc. do?

Guardant Health, Inc. is a precision oncology company that develops blood- and tissue-based diagnostic tests, data solutions, and analytics for cancer care. Its offerings support multiple stages of the oncology pathway, including screening for colorectal cancer, molecular profiling of tumors, treatment selection, monitoring for residual disease and recurrence, and research into tumor biology and therapeutic response.

Company

About Guardant Health, Inc.

Guardant Health, Inc. is a precision oncology company that develops blood- and tissue-based diagnostic tests, data solutions, and analytics for cancer care. Its offerings support multiple stages of the oncology pathway, including screening for colorectal cancer, molecular profiling of tumors, treatment selection, monitoring for residual disease and recurrence, and research into tumor biology and therapeutic response. Products such as Guardant360, Guardant Reveal, Guardant360 Tissue, and Shield provide clinicians and researchers with genomic, epigenomic, transcriptomic, and circulating tumor DNA insights. The company also serves biopharmaceutical organizations through companion diagnostic development, clinical testing services, technology licensing, and real-world data solutions. Its software and data platforms help connect molecular findings with clinical outcomes and relevant research opportunities. Headquartered in Palo Alto, California, Guardant Health, Inc. operates across healthcare, biotechnology, clinical diagnostics, and biopharmaceutical markets, contributing to the broader use of precision medicine in cancer prevention, diagnosis, treatment, and monitoring.

CEO Dr. Helmy Eltoukhy Ph.D. · 2,490 employees · United States · https://guardanthealth.com